Omalizumab and the World Health Organization. It is also used to treat people 12 years and above with chronic spontaneous urticaria (also called chronic idiopathic urticaria), which cannot be treated with elevated doses of H1-antihistamines. The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Like other protein and antibody drugs, omalizumab also causes anaphylaxis, although at a relatively low frequency among antibody drugs. The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody. The
Tarantula cases resolved completely with the use of benzodiazepines and magnesium. In all cases, seeking medical aid is advised. Because other proteins are included when a toxin is injected, some individuals may suffer severe symptoms due to an allergic reaction rather than to the venom. Such allergic effects can be life-threatening. Before biting, tarantulas may signal their intention to attack by rearing up into a "threat posture", which may involve raising their prosoma and lifting their front legs into the air, spreading and extending their fangs, and (in certain species) making a loud hissing by stridulating. Tarantulas often hold this position